Modalis Therapeutics Corporation (4883.T)
JPY 103.0
(-1.9%)
JPY 103.0
(-1.9%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -731 Thousand JPY | 99.12% |
| 2022 | -83.17 Million JPY | -7661.36% |
| 2021 | 1.1 Million JPY | -99.68% |
| 2020 | 342 Million JPY | -46.89% |
| 2019 | 644 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | - JPY | 0.0% |
| 2024 Q2 | - JPY | 0.0% |
| 2023 Q1 | -321 Thousand JPY | 99.04% |
| 2023 Q4 | - JPY | 0.0% |
| 2023 Q3 | - JPY | 0.0% |
| 2023 FY | - JPY | 100.0% |
| 2023 Q2 | - JPY | 100.0% |
| 2022 Q3 | -32.04 Million JPY | 0.0% |
| 2022 FY | -83.17 Million JPY | -7661.36% |
| 2022 Q4 | -33.27 Million JPY | -3.82% |
| 2021 FY | 1.1 Million JPY | -99.68% |
| 2020 FY | 342 Million JPY | -46.89% |
| 2019 FY | 644 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 48.75 Billion JPY | 100.001% |
| Takeda Pharmaceutical Company Limited | 2184.96 Billion JPY | 100.0% |
| Sumitomo Pharma Co., Ltd. | 187.98 Billion JPY | 100.0% |
| Shionogi & Co., Ltd. | 369.08 Billion JPY | 100.0% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.54 Billion JPY | 100.021% |
| Nippon Shinyaku Co., Ltd. | 97.01 Billion JPY | 100.001% |
| Kaken Pharmaceutical Co., Ltd. | 38.22 Billion JPY | 100.002% |
| Eisai Co., Ltd. | 586.41 Billion JPY | 100.0% |
| Morishita Jintan Co., Ltd. | 5.99 Billion JPY | 100.012% |
| Hisamitsu Pharmaceutical Co., Inc. | 78.97 Billion JPY | 100.001% |
| Mochida Pharmaceutical Co., Ltd. | 52.07 Billion JPY | 100.001% |
| Fuso Pharmaceutical Industries,Ltd. | 13.51 Billion JPY | 100.005% |
| Nippon Chemiphar Co., Ltd. | 7.73 Billion JPY | 100.009% |
| Tsumura & Co. | 68.81 Billion JPY | 100.001% |
| Kissei Pharmaceutical Co., Ltd. | 37.34 Billion JPY | 100.002% |
| Torii Pharmaceutical Co., Ltd. | 24.79 Billion JPY | 100.003% |
| Towa Pharmaceutical Co., Ltd. | 81.38 Billion JPY | 100.001% |
| Fuji Pharma Co., Ltd. | 16.51 Billion JPY | 100.004% |
| Zeria Pharmaceutical Co., Ltd. | 50.18 Billion JPY | 100.001% |
| KYORIN Holdings, Inc. | 51.4 Billion JPY | 100.001% |
| Taiko Pharmaceutical Co.,Ltd. | 1.07 Billion JPY | 100.068% |
| Daito Pharmaceutical Co.,Ltd. | 9.83 Billion JPY | 100.007% |
| SymBio Pharmaceuticals Limited | 4.41 Billion JPY | 100.017% |
| MedRx Co., Ltd | 26 Million JPY | 102.812% |
| Mizuho Medy Co.,Ltd. | 8.02 Billion JPY | 100.009% |
| Solasia Pharma K.K. | 337 Million JPY | 100.217% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 30.66 Billion JPY | 100.002% |
| Sawai Group Holdings Co., Ltd. | 54.31 Billion JPY | 100.001% |
| Cyfuse Biomedical K.K. | 37.74 Million JPY | 101.937% |
| Toho Holdings Co., Ltd. | 112.98 Billion JPY | 100.001% |
| Koa Shoji Holdings Co.,Ltd. | 6.63 Billion JPY | 100.011% |